With the advent of the direct-acting antiviral agents (DAAs) for chronic hepatitis C infection, the treatment paradigm has dramatically changed, especially the duration, tolerability, and response to therapy. The DAAs fall into several classes and are variously indicated in the treatment of one or more genotypes of infection. All these agents are orally administered and, as they are largely renally eliminated (with exceptions), do not require adjustment in mild to moderate renal insufficiency. Most of these agents demonstrate a high barrier to resistance and are extremely well-tolerated by patients. Overall efficacy rates are ≥90%.
The majority of resistance mutations that occurred in patients enrolled in clinical trials who experienced virologic failure include NS3 substitutions (V36A/M/T, F43L, V55I, Y56H, Q80L, I132V, R155K, A156G, D168 [any], P334S, S342P, E357K, V406A/I, T449I, P470S, V23A), NS5A substitutions (K24R, M28A/T/V, Q80E/K/R, H/Q54Y, H58D/P/R, Y93C/H/N), and NS5B substitutions (G307R, C316Y, M4141I/T, E446K/Q, A450V, A553I/T/V, G554S, S556G/R, G558R, D559G/I/N/V, Y561H). Because baseline mutations do not appear to have a clinical impact on achievement of sustained virologic response (SVR), as illustrated by the low virologic failure rates in clinical trials, there is no need to do baseline resistance testing prior to initiating therapy [6] .
Similar to LDV, daclatasvir (DCV) is an NS5A inhibitor. A summary of the pharmacokinetic parameters of DCV is located in Tables 1 and 2 Although the AUC of DCV was predicted to be higher in patients with renal impairment using a regression analysis, this agent does not require dose adjustment at any level of renal impairment [7, 8] . Since it is combined with SOF in clinical practice, the precautions described above with LDV/SOF should be observed. In studies of non-HCV-infected patients with hepatic impairment, DCV was observed to result in AUCs that were lower by 43% (Child-Pugh class A), 38% (Child-Pugh class B), and 36% (Child-Pugh class C) as compared with a matched control group; however, no dose adjustment is required regardless of hepatic function [7] .
In patients with genotype 1a enrolled in clinical trials with DCV, NS5A amino acid polymorphisms at M28, Q30, L31, or Y93 were associated with reduced sustained viral response at 12 weeks (SVR 12 ) rates in patients with cirrhosis [7] . The product labeling for DCV advises to consider screening for these polymorphisms prior to treatment initiation. In patients with genotype 3 infection, the Y93H polymorphism was associated with reduced SVR 12 rates in patients with and without cirrhosis, but recommendations for testing are not noted [7] .
Elbasvir (EBR) is an NS5A inhibitor that is coformulated with grazoprevir (GZR), an NS3/4A protease inhibitor [9] . A summary of the pharmacokinetic parameters of these 2 DAAs is located in Table 1 . No dose adjustment is required for patients with renal impairment. This combination can be used in patients with mild hepatic impairment, but not in those with moderate impairment, due to lack of clinical data. It also cannot be used in those with severe hepatic impairment, due to a 12-fold increase in GZR concentrations that occurs [9] .
In clinical trials of patients with genotype 1a infection, the presence of NS5A polymorphisms at M28, Q30, L31, or Y93 were linked to decreased SVR rates with EBR/GZR, regardless of prior treatment received or presence of cirrhosis [9] . Thus, NS5A resistance testing in patients with genotype 1a HCV infection is recommended prior to initiation of therapy to determine if extended therapy with the addition of RBV is required. In contrast, patients with genotype 1b or genotype 4 infection do not require pretreatment resistance testing, as baseline polymorphisms did not impact SVR rates in clinical trials [9] .
Velpatasvir (VEL) is an NS5A inhibitor that is coformulated with SOF. A summary of the pharmacokinetics of VEL is provided in Table 1 . Although its pharmacokinetics are not impacted by renal dysfunction, its use should be avoided in patients with creatinine clearance <30 mL/minute due to its coformulation with SOF and the risk of accumulation of its metabolite (cite package insert). Patients with decompensated cirrhosis do not require dose adjustment, but do require the addition of RBV as per product labeling [10] .
In clinical trials of patients with genotype 1a infection, the occurrence of both L31V and Y93H/Y93N resulted in a >100-fold reduction in VEL susceptibility, and this was also seen with both L31V and Y93H in genotype 1b, Y93H/S in genotype 3a, and L31V and P32A/L/Q/R in genotype 6 [10] . Reduced susceptibility was also observed with F28S or Y93H in genotype 2b and Y93H in genotype 4a [10] . Unlike the product labeling for EBR/GZR, VEL does not require the use of routine baseline resistance testing prior to treatment initiation.
Voxilaprevir (VOX) is an HCV NS3/4A protease inhibitor that is coformulated with SOF and VEL, and a summary of its pharmacokinetics is provided in Table 1 . Recommendations for use in patients with renal impairment are the same as those for SOF/VEL; however, because of the potential for increased exposure to VOX in patients with Child-Pugh class B or C hepatic impairment, its use is not recommended in these populations [11] . Resistance to VOX occurred with selected amino acid substitutions at NS3/4A protease inhibitor resistance-associated positions 41, 156, and 168. Reduced susceptibility was observed with A156L/T in genotype 1a, A156T/V in genotype 1b, A156L/V in genotype 2a, A156T/V in genotype 3a, and A156L/T/V in genotype 4 [11] .
DRUG INTERACTIONS
Because LDV is only available coformulated with SOF, drug interactions that have been described with SOF must be considered in conjunction with this agent. Discussion of the mechanism behind drug interactions with SOF has been published previously [1] . Similar to SOF, LDV is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BRCP). However, in contrast to SOF, LDV is an inhibitor of these drug transport proteins and may result in increased absorption of substrate medications [2] . Additionally, LDV requires gastric acidity for solubility; thus, acid-reducing agents decrease the concentration of LDV. Administration of this agent should be separated by at least 4 hours with antacids. Use of H2-receptor antagonists should be limited to the equivalent of 40 mg famotidine twice daily and should be administered at the same time as LDV/SOF or 12 hours afterward. Use of proton pump inhibitor therapy should be limited to no more than 20 mg omeprazole or its equivalent dosed at the same time as LDV/SOF [2] . A recent addition to the product labeling of LDV/SOF is its warning against concomitant use with amiodarone, which has resulted in symptomatic bradycardia, including fatal cardiac arrest, via an unknown mechanism [2] . Risk factors for this adverse effect may include presence of underlying cardiac disease, advanced liver diseases, and/or concomitant use of β-blockers. Therefore, it is recommended to avoid use of amiodarone with this therapy. If amiodarone is continued or is discontinued just prior to LDV/SOF treatment, patients must be warned of this interaction and monitored with inpatient telemetry for the first 48 hours of administration, followed by outpatient heart rate monitoring for at least 2 weeks. The drug interaction profile of OBV/PTV/r + DSV is more complex than that of LDV/SOF for a number of reasons. First, because the regimen contains RTV, a strong inhibitor of cytochrome P450 (CYP) 3A4, there are numerous drug-drug interactions that occur, similar to considerations when using this agent as a pharmacokinetic enhancer with protease inhibitors for human immunodeficiency virus (HIV) infection. Additionally, OBV, PTV, and DSV inhibit the UDP glucuronosyltransferase 1 family (UGT1) polypeptide A1; PTV inhibits and utilizes organic anion-transporting polypeptide (OATP) 1B1 and OATP1B3; and PTV, RTV, and DSV inhibit BCRP [6] . Also, the components of this regimen are substrates of a variety of systems and transporters: PTV and RTV are substrates of CYP3A, DSV is a substrate of CYP2C8, and OBV is a minor substrate of some CYP enzymes. All 4 regimen components are substrates of P-gp, whereas all except RTV are substrates of BCRP [6] . As a result, there are numerous agents that are contraindicated for concomitant use with this regimen or require special considerations, and these should be checked in an appropriate current drug reference. It is critical to assess each patient's medication profile carefully using up-to-date drug interactions references prior to initiation of this regimen.
DCV is a CYP3A4 and a P-gp substrate; its drug interaction profile is also more complicated than that of LDV/SOF. Additionally, it is a weak inducer of CYP3A4 and an inhibitor of P-gp, OATP1B1, OATP1B3, and BRCP, which also add to its interaction profile [7, 8] . Avoidance of strong inducers with DCV is necessary. Dosage increases or decreases are also necessary due to drug interactions, and these should be assessed using a current drug reference. Because numerous studies have assessed drug interactions between DCV and antiretroviral regimens used for treatment of HIV, the dosing strategy for DCV when used in coinfected patients is straightforward based on product labeling. Both EBR and GZR are substrates of CYP3A and P-gp; their drug interaction profile is similar to that seen with DCV. Additionally, GZR is a substrate of OATP1B1/3. Avoidance of inhibitors of OATP1B1/3 and CYP3A as well as inducers of CYP3A is required.
Given that VEL and VOX are only available coformulated with SOF, drug interactions that have been described with SOF must be considered in conjunction with these agents, as discussed above with LDV/SOF. Similar to SOF and LDV, VEL and VOX are substrates of P-gp and BRCP. Also similar to LDV, VEL and VOX are inhibitors of these drug transport proteins and may result in increased absorption of substrate medications [10, 11] . Also similar to LDV, VEL requires gastric acidity for solubility; thus, acid-reducing agents decrease the concentration of VEL and require the same staggering of doses with use of antacids or H2-receptor antagonists as described above. Use of proton pump inhibitor therapy should be avoided if possible; if use is absolutely necessary, it should be limited to no more than 20 mg omeprazole or its equivalent dosed with food 4 hours prior to SOF/VEL [10] . Unlike LDV, VEL is metabolized by CYP450 2B6, 2C8, and 3A4. Regardless of regimen selected, it is imperative to carefully assess for drug interactions, as there are numerous contraindications and precautions to keep in mind.
CLINICAL STUDIES
The efficacy of LDV/SOF is based on 4 trials, LONESTAR and ION-1, -2, and -3 [12] [13] [14] [15] , detailed in Table 3 . SAPPHIRE-I and II [16, 17] were the only trials with a placebo arm; PEARL III and IV [18] evaluated PTV/r, OBV, and DSV with or without (±) RBV in genotype 1b or 1a patients, respectively. The C-WORTHY trial [19] evaluated the efficacy of GZR and EBR ± RBV.
More recently, the ASTRAL-1 trial [20] , evaluated SOF + VEL for 12 weeks in subjects with HCV genotype 1, 2, 4, 5, or 6. The primary endpoint in all the trials was SVR defined as HCV RNA below the lower limit of quantification 12 weeks after the discontinuation of active treatment (SVR 12 ). Additionally, RBV, when used, was used in a weight-based fashion (1000-or 1200-mg daily doses). Many of these trials included a subset of subjects who were treatment experienced with prior regimens of PEG-IFN, RBV, and protease inhibitors such as boceprevir or telaprevir, a surrogate for a harder-to-treat subgroup.
The cirrhotic population was evaluated in SIRIUS [21] using LDV/SOF, and SOLAR-1 and -2 [22, 23] , which included RBV in addition to LDV/SOF and had a cohort that was pretransplant, as well as posttransplant (Table 4) . TURQUOISE-II [24] evaluated PTV/r, OBV, and DSV ± RBV, evaluating subgroups based on prior response to PEG-IFN. The C-WORTHY trial [25] evaluated GZR and EBR ± RBV for 12 or 18 weeks. ASTRAL-4 [26] evaluated the pan-genotypic combination of SOF/VEL ± RBV. Table 5 summarizes the data in non-genotype 1 patients. While SOF/RBV [27, 28] were the first to be studied, other studies such as PEARL-1 [29] evaluated genotype 4 patients, and ALLY-3 and ALLY-3+ [30, 31] evaluated DCV + SOF in treatment-naive and -experienced patients, including advanced liver disease. C-EDGE [32] evaluated a few genotype 4 and genotype 6 patients. ASTRAL-1 evaluated genotypes 1, 2, 4, 5, and 6 with SOF/VEL [20] , whereas ASTRAL-2/3 evaluated genotype 2 and 3 patients [33] .
In the HCV/HIV-coinfected population (Table 6 ), PHOTON-1 [34] and PHOTON-2 [35] evaluated SOF/RBV, including in patients with cirrhosis. ION-4 [36] evaluated LDV/ SOF; ALLY-2 [37] evaluated DCV/SOF; TURQUOISE-I [38] looked at PTV/r and OBV/DSV/RBV; and C-WORTHY [39] and C-EDGE [40] evaluated GZR/EBR ± RBV.
Data are emerging in the pre-and posttransplant population (Table 6) , with SOF/RBV being the first [41] . ALLY-1 evaluated DCV/SOF/RBV in this population [42] , whereas CORAL-1 evaluated PTV/r, OBV, and DSV with RBV [43] . The C-SURFER study [44] evaluated GZR/EBR without RBV in chronic kidney disease stage 4 and 5 (Table 7) .
Most recently, the first regimen in DAA-experienced treatment failures was just approved by the US Food and Drug Administration (FDA). Voxilaprevir was studied in the POLARIS-1 and -4 studies (SOF/VEL/VOX) and has demonstrated significant promise across all genotypes [45] .
ADVERSE EFFECTS
LDV with SOF, in a pooled analysis of 3 phase 3 trials [2, 14, 15] demonstrated it was well-tolerated, with ≤1% of discontinuations due to adverse effects (AEs). Fatigue and headache were the commonest AEs in >10% of patients. Rarer issues included nausea, diarrhea, and insomnia. Less than 5% of patients experienced elevations in lipase or total bilirubin [2, 14, 15] .
Six phase 3 clinical trials of OBV/PTV/r + DSV (SAPPHIRE-I and -II, TURQUOISE-II, PEARL-II, -III, and -IV) with >2000 patients [6, 15, 16, 18, 29] , when used with or without RBV, was well-tolerated, with <1% of patients discontinuing treatment with AEs. Fatigue, nausea, pruritus, skin reactions, and asthenia occurred in >5% of patients [6] . Skin reactions were commoner in those receiving RBV, the majority being mild, and there were no severe skin reactions. Asymptomatic elevations in alanine aminotransferase occurred in 1% subjects, but in those taking concurrent ethinyl estradiol it was 25%, thus precluding its use with this form of hormonal therapy.
Other estrogen-containing products should be used with caution. The product label recommends liver function testing in all patients during the first 4 weeks of treatment and subsequently, as needed. Bilirubin elevations alone occurred in 15% of patients treated with concomitant RBV, as opposed to 2% without RBV [6] . Given RBV's propensity for hemolytic anemia, the phase 3 trials of OBV/PTV/r + DSV with RBV included assessment of changes in hemoglobin [6, 15, 16, 18, 29, 34, 46, 47] . Patients taking RBV had a mean decrease of 2.4 g/dL, whereas only a 0.5 g/dL decrease occurred without RBV. Only 7% of patients required dose reduction and <1% patients had their hemoglobin drop to <8 g/dL during treatment [6] .
Approximately 2400 patients enrolled in 3 clinical trials, including ALLY-1, ALLY-2, and ALLY-3, contributed to the AE profile of DCV [7, 38, 41, 42] . Headache and fatigue were commonest in ALLY-2 and ALLY-3, in ≤15% of patients [7, 38, 42] . Fatigue occurred in 15% and 17% of cirrhotic and liver transplant patients, respectively, enrolled in ALLY-1, likely due to RBV [7, 41] . Hemoglobin <8.9 g/dL occurred in 6% of those in ALLY-1, but none in ALLY-2/ALLY-3, again due to RBV [7, 41] .
Subjects on EBV/GZR had similar complaints of fatigue and headache [9, 32, 39] . Elevations in bilirubin to >2.5 times the upper limit of normal occurred in 1%-6% of patients. RBV led to an 8% incidence of anemia, although <1% had hemoglobin decrease to <8.5 g/dL [9] .
In 1035 patients without cirrhosis or with compensated cirrhosis treated with SOF/VEL in 3 clinical trials [25, 26] , the commonest AEs included headache, fatigue, and nausea [10] . The ASTRAL-4 trial had 87 patients who received SOF/VEL/ RBV for 12 weeks [23] where fatigue, anemia, nausea, headache, and diarrhea occurred in at least 10% of patients [10] . The commonest AEs with SOF/VEL/VOX were also headache, fatigue, nausea, and diarrhea, occurring in at least 10% of patients [11] .
AVAILABILITY AND COST CONSIDERATIONS
All of the currently available HCV medications are packaged in bottles or cartons containing a 28-day supply of drug. LDV is available in a coformulated combination tablet with SOF. This product, known by the trade name Harvoni, contains 90 mg LDV The numerator is the number of subjects cured and the denominator indicates the total number of subjects in that group.
Abbreviations: DCV, daclatasvir; EBR, elbasvir; GT, genotype; GZR, grazoprevir; OBV, ombitasvir; PTV/r, paritaprevir/ritonavir; RBV, ribavirin; SOF, sofosbuvir; SVR 12 , sustained virologic response at 12 weeks after completion of treatment; VEL, velpatasvir. a ALLY-3+ enrolled some subjects with cirrhosis.
b Please see the "Clinical Studies" section for expansions of study names.
and 400 mg SOF, and is dosed as 1 tablet once daily, regardless of meals [2] . It is approved for patients with genotypes 1, 4, 5, and 6 infection, and duration of therapy varies depending upon individual treatment history and liver histology. Table 2 lists the FDAapproved indications and duration of therapy for this product. OBV, PTV, and RTV are coformulated in a tablet, whereas DSV is available by itself in a tablet formulation. All of these agents are only available copackaged in a product known by the trade name Viekira Pak, and all 4 agents are coformulated as Viekira XR [6, 49] . The Viekira Pak regimen is dosed as 2 OBV 12.5 mg/PTV 75 mg/RTV 50 mg tablets once daily in the morning with a meal, and 1 DSV 250 mg tablet twice daily with meals, whereas the Viekira XR regimen is dosed as 3 extended-release tablets taken at the same time with a meal, with each tablet containing DSV 200 mg/ OBV 8.33 mg/PTV 50 mg/RTV 33.33 mg [48] . Technivie is a product marketed for patients with genotype 4 HCV infection. It is dosed as 2 tablets, each containing OBV 12.5 mg/ PTV 75 mg /RTV 50 mg [48, 50] Weight-based RBV (eg, 1000 mg/day for patients weighing <75 kg; 1200 mg/day for those ≥75 kg) should be used in those patients requiring its use in combination with these products. the FDA-approved labeling and duration of therapy for this product, along with indications to add RBV.
DCV is available as a single-entity tablet, in 30-mg, 60-mg, and 90-mg strengths, known by the trade name Daklinza. EBR and GZR are available in a coformulated tablet containing 50 mg of EBR and 100 mg of GZR, known as Zepatier. Table 2 summarizes the FDA-approved labeling and duration of therapy for these agents.
VEL is available in a coformulated tablet containing 100 mg VEL and 400 mg SOF, known as Epclusa. Regardless of genotype, SOF/VEL is dosed as 1 tablet daily for 12 weeks for patients without cirrhosis or with compensated cirrhosis. For those patients with decompensated cirrhosis, dosing is 1 tablet daily combined with weight-based RBV for a total of 12 weeks [10] .
VOX is available in a coformulated tablet containing 100 mg VOX, 100 mg VEL, and 400 mg SOF, known as Vosevi. Regardless of indication, it is dosed as 1 tablet daily for 12 weeks [11] .
Drug pricing has been an issue at the forefront of newer treatment modalities for HCV infection. As of January 2017, the average wholesale price (AWP) of a 4-week supply of LDV/ SOF is $37 800, thus resulting in pricing of $75 600, $113 400, and $226 800 for 8, 12, and 24 weeks of therapy, respectively [51] . The AWP of a 4-week supply of OBV/PTV/r/DSV is $33 328, resulting in a cost of $99 984 or $100 293 for a 12-week supply without or with RBV, respectively, and $200 586 for a 24-week supply with RBV (both calculations are based upon a patient weighing >75 kg). The AWP of a 4-week supply of DCV ($25 200) plus SOF ($33 600) is $58 800, resulting in a cost of $176 400 for a 12-week supply without RBV, and $176 709 with RBV [51] . The AWP of a 4-week supply of EBR/GZR is $21 840, resulting in a cost of $65 520 for a 12-week supply without RBV and $65 829 with RBV, whereas 16 weeks of treatment including RBV would cost $87 772 [51] . The AWP of a 12-week supply of SOF/VEL is $ 89 712 without RBV and $90 021 with RBV, and the AWP of a 12-week supply of SOF/VEL/VOX is $89 712 [52] . The manufacturers of these products are currently providing discounted pricing through contracts with pharmacy benefit managers. For example, CVS Health Corporation, Anthem, Inc, Humana, and Harvard Pilgrim have previously contracted with Gilead Sciences to list LDV/SOF as preferred on their formularies, while Express Scripts signed a contract with AbbVie to list OBV/PTV/r/DSV as the preferred regimen [52] . It is hoped that competition between the manufacturers of these 2 products and those of agents that will be approved in the future will drive prices lower, permitting more widespread use of these agents.
CONCLUSIONS
The rapid introduction of DAAs has revolutionized the treatment of chronic HCV infection. While very similar in terms of effectiveness and AEs, they differ vastly in their administration, drug interactions, and FDA-approved uses. Additionally, considerations for patients coinfected with HIV include careful assessment of drug interactions with antiretroviral therapy. 
